Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
An Open-Label, Multicenter, Phase 1 Study of IGM-7354 in Adult Participants With Relapsed and/or Refractory Cancer
Sponsor: IGM Biosciences, Inc.
This PHASE1 trial investigates Solid Tumor and is currently completed. IGM Biosciences, Inc. leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Aug 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Jun 2023 [monthly]
Recruiting PHASE1
First recorded
Jan 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- IGM Biosciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .